tradingkey.logo
tradingkey.logo
Search

Protalix Biotherapeutics Inc

PLX
Add to Watchlist
2.215USD
+0.195+9.65%
Close 06/18, 16:00ETQuotes delayed by 15 min
178.47MMarket Cap
11.47P/E TTM

Earnings Forecast

Currency: USD Updated: 2026-06-17
Previous score
8.00
Change
0
The current earnings forecast score of Protalix Biotherapeutics Inc is 8.00, ranking 55 out of 157 in the Pharmaceuticals industry. The average price target is 12.50, with a high of 13.00 and a low of 12.00.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
11.000
Target Price
+433.98%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Protalix Biotherapeutics Inc
PLX
1
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

What is Protalix Biotherapeutics Inc's expected revenue for the next quarter?

Protalix Biotherapeutics Inc's expected revenue is 12.93M.

What is Protalix Biotherapeutics Inc's price target?

Analysts forecast that Protalix Biotherapeutics Inc's price target is USD 12.50, with the highest forecast at USD 13.00 and the lowest forecast at USD 12.00.

How have Protalix Biotherapeutics IncPLX's recent earnings per share performed?

The market expectation was USD 0.23, while Protalix Biotherapeutics IncPLX's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD -0.01.

What is the analyst rating for Protalix Biotherapeutics Inc?

Based on the ratings of Protalix Biotherapeutics Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
KeyAI